Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of Tenaya Therapeutics in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.16) per share for the quarter, up from their prior estimate of ($0.17). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.66) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06).

A number of other research analysts have also recently commented on TNYA. Morgan Stanley decreased their price target on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Chardan Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Friday, May 9th. Finally, Canaccord Genuity Group cut their price target on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $0.39 on Monday. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $4.78. The company has a 50 day moving average price of $0.53 and a 200 day moving average price of $1.35. The stock has a market capitalization of $34.54 million, a P/E ratio of -0.27 and a beta of 2.99.

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the purchase, the insider now owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This trade represents a 262.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 19,621 shares of company stock valued at $10,595 in the last quarter. Corporate insiders own 32.76% of the company’s stock.

Institutional Trading of Tenaya Therapeutics

Institutional investors have recently bought and sold shares of the business. Woodline Partners LP purchased a new position in shares of Tenaya Therapeutics in the 4th quarter valued at about $28,000. Commerce Bank purchased a new position in Tenaya Therapeutics in the fourth quarter valued at approximately $29,000. Mariner LLC acquired a new stake in Tenaya Therapeutics during the fourth quarter worth approximately $30,000. Ground Swell Capital LLC purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter worth approximately $32,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Tenaya Therapeutics in the 1st quarter valued at $33,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.